Drugs – Generic
(HITK) Hi-Tech Pharmacal – Reports Another Earnings Surprise
Hi-Tech Pharmacal Co. (HITK) continues to trade at great valuations and have plenty of earnings momentum.
Company Description
Hi-Tech Pharmacal makes generic and branded pharmaceuticals,...
(PRX) Par Pharmaceutical Companies – Earnings Surprised in the Fourth Quarter by 14%
Par Pharmaceutical Companies Inc. (PRX) has surprised on the Zacks Consensus Estimate 4 quarters in a row by an average of 47%. PRX is trading with a forward P/E of only 12.6.
Company Description
Par...
(MYL) Mylan Earns FDA Approval For Laxative Candidate
Mylan Inc. (MYL) received approval from the US Food and Drug Administration (FDA) for the generic version of Braintree Laboratories’ NuLytely, a laxative. The company is eligible to ship the product...
(MYL) Mylan Strengthens Drug Portfolio
Mylan Inc. (MYL) has entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs – Actoplus Met and Actos, which recorded 2009 sales of $459 million and $3.4 billion, respectively.
Following...
($MYL) Mylan Beats Earnings Expectations – Outlook Robust
Mylan (MYL) reported fourth quarter earnings per share (EPS) of 33 cents, surpassing the Zacks Consensus Estimate of 30 cents and 26 cents in the prior-year period. For the full year 2009, EPS came in at $1.30,...
(WPI) Watson Pharmaceuticals Sees 16 Analysts Raising Fourth Quarter Estimates
Watson Pharmaceuticals, Inc. (WPI) reports fourth-quarter results on February 23, with the current Zacks Consensus Estimate at 72 cents per share. Estimates appear to be modestly up, with one of the 16 analysts...
(WPI) Watson Pharmaceuticals Set to Top Expectations
Watson Pharmaceuticals, Inc. (WPI) recently announced that it expects 2009 earnings to meet or exceed guidance provided by the company in Nov. 2009. The company had earlier guided towards earnings in the range...
(WPI) Watson Pharmaceuticals Coverage Initiated at Neutral
We recently initiated coverage on Watson Pharmaceuticals, Inc. (WPI) with a “Neutral” recommendation and a target price of $42. The company enjoys a strong position in the generics market. We...
(HITK) Hi-Tech Pharmacal Co. – Earnings Estimates Jump Big!
Hi-Tech Pharmacal Co (HITK) estimates are surging following the latest earnings report, which showed earnings rise more than 600%.
Company Description
Hi-Tech...
(WPI) Watson Pharmaceuticals Inc Acquires Arrow Group
Watson Pharmaceuticals Inc. (WPI) recently completed its acquisition of privately held Arrow Group. The company closed its $1.75 billion cash and stock buyout of Arrow after receiving the green signal from...
(PRX) Par Pharmaceutical Cos. – Revenue Doubles – Earnings Estimates Jump
Par Pharmaceutical Cos. (PRX) continues to climb as analysts raise estimates on another earnings surprise.
Company Description
Par Pharmaceutical makes generic drugs...
(MYL) Mylan Wins FDA Approval for Their Abbreviated New Drug Application
Recently, Mylan Inc.‘s (MYL) subsidiary, Matrix Laboratories received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release...
(MYL) Mylan Beats Expectations – Raises Outlook
Mylan, Inc. (MYL) reported third quarter earnings per share of 32 cents, above both the Zacks Consensus Estimate of 27 cents and 23 cents in the prior-year period. The company reported revenues of $1.26 billion,...
(PRX) Par Pharmaceutical Companies, Inc. – Beat by 35.42% in the Second Quarter
Par Pharmaceutical Companies, Inc. (PRX) has surprised on the Zacks Consensus Estimate 3 out of the last 4 quarters by an average of 101.93%. With earnings estimates jumping, the company has a PEG ratio of just 0.2.
Company...
(PRX) Par Pharmaceutical Companies – Beat by 35.42% in the Second Quarter
Par Pharmaceutical Companies, Inc. (PRX) has surprised on the Zacks Consensus Estimate 3 out of the last 4 quarters by an average of 101.93%. With earnings estimates jumping, the company has a PEG ratio of just 0.2.
Company Description
Par...
(MYL) Mylan Settles Dispute with Pfizer
Recently, Mylan (MYL) announced the settlement of its dispute with Pfizer (PFE) related to the patent of antifungal drug Vfend (voriconazole). Now Mylan can launch an authorized generic version of the drug in two dosage forms of 50 mg and...
(PRX) Top Performer for Thurs: Par Pharmaceutical Companies
Par Pharmaceutical Companies, Inc. (PRX) received a brokerage firm upgrade today, which is helping it to gain during a rather muted morning session.
In addition, PRX has been enjoying rising earnings estimates that have pushed the 2009 and 2010 Zacks...
(HITK) Top Performer for Wed: Hi-Tech Pharmacal- Zacks #1 Rank Top Performers
Hi-Tech Pharmacal Co., Inc. (HITK) enjoyed a strong performance from generic pharmaceuticals in its fiscal first quarter, leading to a sharp earnings surprise and large revenue growth.
With a gain of only around 3.8%, HITK is a top-performing Zacks...
(MYL) Mylan’s Portfolio Strengthens
We are pleased to hear that Mylan (MYL) has begun to market the generic version of BenzaClin (1% Clindamycin and 5% Benzoyl Peroxide Gel) for acne treatment, which was originally manufactured by Sanofi-Aventis (SNY). The drug has been developed...
(MYL) Mylan Drug Gets Tentative OK
Yesterday, Mylan Inc. (MYL) announced that its Indian subsidiary, Matrix Laboratories, received tentative approval from the US Food and Drug Administration (FDA) under the President’s Emergency Plan for AIDS Relief (PEPFAR) for its generic version of...
(PRX) Par Pharmaceutical Companies, Inc. – Value – Zacks Rank Buy
Par Pharmaceutical Companies, Inc. (PRX), the generic drug manufacturer, saw revenue grow 32% as sales popped for Metroprolol, the generic version of angina drug Toprol. The company’s surprise of 81.48% had analysts scrambling to raise estimates. PRX is trading...
(WPI) Watson Pharmaceuticals, Inc. – Value – Zacks Rank Buy
Watson Pharmaceutical Inc. (WPI), a generic and branded drug manufacturer, didn’t disappoint when it reported third quarter results last week. The company easily surprised on Wall Street estimates by 18.37% and raised 2009 guidance.
Adjusted earnings...
(WPI) Watson Pharmaceuticals, Inc. – Value – Zacks Rank Buy
Watson Pharmaceutical Inc. (WPI), a generic and branded drug manufacturer, has surprised on earnings 3 out of the last 4 quarters by an average of 5.34%. Consensus estimates are rising going into the Apr 30 first-quarter earnings announcement. WPI has a forward...
(MYL) Mylan, Inc. – Momentum – Zacks Rank Buy
Mylan, Inc.’s (MYL) share price continues to trend higher on consistent earnings and higher estimates. The company is scheduled to report its first-quarter results on May 7.
Estimates
Earnings...
(WPI) Watson Pharmaceuticals Inc. – Aggressive Growth – Zacks Rank Buy
Watson Pharmaceuticals, Inc. (WPI) has reported another earning surprise and analysts are raising estimates heading into the next announcement.
Company Description
Watson Pharmaceuticals, Inc. is a pharmaceutical...
(MYL) Mylan, Inc. – Momentum – Zacks Rank Buy
Mylan, Inc.’s (MYL) share price continues to head higher after the company’s solid fourth-quarter and full-year results. The analyst community is bullish on this stock, projecting 44% earnings growth in the next-year period.
Company...